Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ATOS's Cash to Debt is ranked higher than
84% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. ATOS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ATOS' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 396.38 Max: No Debt
Current: No Debt
Equity to Asset 0.73
ATOS's Equity to Asset is ranked higher than
67% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ATOS: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
ATOS' s Equity to Asset Range Over the Past 10 Years
Min: -0.66  Med: 0.79 Max: 0.95
Current: 0.73
-0.66
0.95
F-Score: 4
Z-Score: -7.14
M-Score: 53.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -285.95
ATOS's Operating margin (%) is ranked lower than
81% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. ATOS: -285.95 )
Ranked among companies with meaningful Operating margin (%) only.
ATOS' s Operating margin (%) Range Over the Past 10 Years
Min: -171450  Med: -2243.72 Max: -1051.66
Current: -285.95
-171450
-1051.66
Net-margin (%) -285.02
ATOS's Net-margin (%) is ranked lower than
81% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. ATOS: -285.02 )
Ranked among companies with meaningful Net-margin (%) only.
ATOS' s Net-margin (%) Range Over the Past 10 Years
Min: -172100  Med: -2245.24 Max: -1053.94
Current: -285.02
-172100
-1053.94
ROE (%) -145.20
ATOS's ROE (%) is ranked lower than
88% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. ATOS: -145.20 )
Ranked among companies with meaningful ROE (%) only.
ATOS' s ROE (%) Range Over the Past 10 Years
Min: -972.32  Med: -148.34 Max: -136.71
Current: -145.2
-972.32
-136.71
ROA (%) -116.56
ATOS's ROA (%) is ranked lower than
93% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. ATOS: -116.56 )
Ranked among companies with meaningful ROA (%) only.
ATOS' s ROA (%) Range Over the Past 10 Years
Min: -223  Med: -118.92 Max: -102.65
Current: -116.56
-223
-102.65
ROC (Joel Greenblatt) (%) -4721.47
ATOS's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. ATOS: -4721.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATOS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6677.4  Med: -3477.21 Max: -1141.33
Current: -4721.47
-6677.4
-1141.33
» ATOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ATOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.87
ATOS's P/B is ranked higher than
90% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.84 vs. ATOS: 0.87 )
Ranked among companies with meaningful P/B only.
ATOS' s P/B Range Over the Past 10 Years
Min: 0.73  Med: 3.09 Max: 22.55
Current: 0.87
0.73
22.55
P/S 1.13
ATOS's P/S is ranked higher than
82% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.78 vs. ATOS: 1.13 )
Ranked among companies with meaningful P/S only.
ATOS' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 72.67 Max: 221
Current: 1.13
0.96
221
Current Ratio 2.90
ATOS's Current Ratio is ranked higher than
52% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ATOS: 2.90 )
Ranked among companies with meaningful Current Ratio only.
ATOS' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.90 Max: 16.36
Current: 2.9
0.01
16.36
Quick Ratio 2.85
ATOS's Quick Ratio is ranked higher than
57% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ATOS: 2.85 )
Ranked among companies with meaningful Quick Ratio only.
ATOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.87 Max: 16.36
Current: 2.85
0.01
16.36
Days Inventory 8.90
ATOS's Days Inventory is ranked higher than
93% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. ATOS: 8.90 )
Ranked among companies with meaningful Days Inventory only.
ATOS' s Days Inventory Range Over the Past 10 Years
Min: 21.41  Med: 21.41 Max: 21.41
Current: 8.9
Days Sales Outstanding 66.07
ATOS's Days Sales Outstanding is ranked lower than
51% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. ATOS: 66.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 80.15  Med: 145.02 Max: 206.79
Current: 66.07
80.15
206.79
Days Payable 115.77
ATOS's Days Payable is ranked higher than
79% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. ATOS: 115.77 )
Ranked among companies with meaningful Days Payable only.
ATOS' s Days Payable Range Over the Past 10 Years
Min: 182.87  Med: 310.33 Max: 635.81
Current: 115.77
182.87
635.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.73
ATOS's Price/Net Cash is ranked higher than
91% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.08 vs. ATOS: 1.73 )
Ranked among companies with meaningful Price/Net Cash only.
ATOS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.68  Med: 5.72 Max: 390
Current: 1.73
2.68
390
Price/Net Current Asset Value 1.24
ATOS's Price/Net Current Asset Value is ranked higher than
94% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.80 vs. ATOS: 1.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATOS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.49  Med: 5.46 Max: 130
Current: 1.24
2.49
130
Price/Tangible Book 1.08
ATOS's Price/Tangible Book is ranked higher than
88% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. ATOS: 1.08 )
Ranked among companies with meaningful Price/Tangible Book only.
ATOS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.45  Med: 5.03 Max: 97.5
Current: 1.08
2.45
97.5
Price/Median PS Value 0.02
ATOS's Price/Median PS Value is ranked higher than
99% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. ATOS: 0.02 )
Ranked among companies with meaningful Price/Median PS Value only.
ATOS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 1.12 Max: 2.41
Current: 0.02
0.05
2.41

More Statistics

Revenue(Mil) $6
EPS $ -0.63
Beta1.46
Short Percentage of Float0.82%
52-Week Range $0.14 - 2.65
Shares Outstanding(Mil)30.45

Analyst Estimate

Dec15
Revenue(Mil)
EPS($) -0.50
EPS without NRI($) -0.50

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:YAG.Germany,
Atossa Genetics Inc was incorporated in Delaware on April 2009. The Company is a healthcare company, engaged in the improvement of breast health through the development of a suite of laboratory developed tests (LDTs), FDA cleared medical devices and therapeutics. Its laboratory tests are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), and are intended to address each of the four stages of the breast health care path: the cytological analysis of nipple aspirate fluid (NAF); the cytological analysis of ductal lavage fluid collected from each individual breast duct with its proprietary microcatheters; the profiling of newly diagnosed breast cancers through the determination of gene expression profiles in breast cancer biopsy tissue; and the monitoring of breast cancer survivors for pre-clinical recurrence through a blood test for circulating tumor cells. The Company's medical devices under development include the ForeCYTE Breast Aspirator (510(k) pending, not for sale in the United States) intended for the collection of NAF for cytological testing at a laboratory, intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential use by breast surgeons. It owns 137 issued patents (45 in the United States and at least 92 in foreign countries), and 11 pending patent applications (9 in the United States and 2 pending International Patent Cooperation Treaty (PCT) application) directed to its products, services, and technologies. The Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA's implementing regulations, govern registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, and post-market surveillance. Medical devices and the manufacturers are also subject to inspection by the FDA. The FDCA, supplemented by other federal and state laws, also provides civil and criminal penalties for violations of its provisions.
» More Articles for ATOS

Headlines

Articles On GuruFocus.com
Atossa Genetics (ATOS) Soars on Distribution Deal, Conn's (CONN) Rating Boosted Feb 09 2015 

More From Other Websites
Are You Communicating or Collaborating? Feb 02 2016
ATOSSA GENETICS INC Files SEC form 8-K, Other Events Jan 29 2016
ATOS Sells Diagnostics and Becomes a Pure Play Biopharma Jan 26 2016
Atossa Genetics Completes Sale of Its Wholly-Owned Subsidiary The National Reference Laboratory for... Dec 17 2015
Atossa Genetics Completes Sale of Its Wholly-Owned Subsidiary The National Reference Laboratory for... Dec 17 2015
ATOSSA GENETICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Dec 16 2015
Atossa Genetics to Announce Third Quarter 2015 Financial Results and Provide a Company Update on... Dec 09 2015
Atossa Genetics Announces Third Quarter 2015 Financial Results and Provides Company Update Dec 09 2015
ATOSSA GENETICS INC Financials Dec 08 2015
Atossa Genetics, Inc. Earnings Q3, 2015 Dec 02 2015
ATOSSA GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 12 2015
Atossa Genetics Announces Third Quarter 2015 Financial Results and Provides Company Update Nov 12 2015
Q3 2015 Atossa Genetics Inc Earnings Release - After Market Close Nov 12 2015
Atossa Genetics to Announce Third Quarter 2015 Financial Results and Provide a Company Update on... Nov 10 2015
Atossa Genetics Hires Janet Rose Rea, M.S.P.H. as VP Regulatory Affairs and Quality Oct 14 2015
Atossa Genetics to Present at Upcoming Investor Conferences Oct 09 2015
ATOSSA GENETICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Oct 02 2015
Atossa Genetics, Inc. Earnings Q2, 2015 Oct 01 2015
Atossa Genetics' Laboratory Receives ISO 15189:2012 Certification Sep 25 2015
ATOS: Two Phase II Clinical Trials Underway Sep 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK